Company news
Duality Biotherapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Next Day Disclosure Return
November 3, 2026
Next Day Disclosure Return
November 2, 2026
Next Day Disclosure Return
October 30, 2026
Voluntary announcement - voluntary lock-up undertaking by directors and senior management
October 29, 2026
Voluntary announcement - update on share repurchases and proposed increase in shareholding by chairman of the board
October 28, 2026
Next Day Disclosure Return
October 28, 2026
Next Day Disclosure Return
October 27, 2026
Inside information - update on the dynasty-BREAST02 global Phase 3 clinical trial of trastuzumab pamirtecan
October 26, 2026
Next Day Disclosure Return
October 16, 2026
Next Day Disclosure Return
October 15, 2026
Next Day Disclosure Return
October 14, 2026
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
October 9, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
September 30, 2026
Next Day Disclosure Return
September 29, 2026
Next Day Disclosure Return
September 28, 2026
2026 Interim report
September 28, 2026
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
April 9, 2026
DualityBio (9606.HK) Announces 2025 Annual Results
March 24, 2026
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
July 21, 2025
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
July 8, 2025
Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting
June 4, 2025
FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
May 22, 2025